Lipid polycation DNA gene delivery system - Targeted Genetics/Elan

Drug Profile

Lipid polycation DNA gene delivery system - Targeted Genetics/Elan

Latest Information Update: 14 Apr 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Corporation; Targeted Genetics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Apr 2004 Targeted Genetics formally concludes its collaboration with Elan
  • 06 Oct 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top